

Integrating clinical and behavioral studies in primary care

<mark>Κωνσταντ</mark>ίνος Α. Ζήσης, MSc

Pharmaceutical Product Development (PPD), Site Intelligence and Activation Συνεργάτης, Ινστιτούτο Οικονομικών της Υγείας

Topics to be discussed

Clinical trial definition

The drug development process, clinical trial statistics

- Documents in clinical trials: a brief review
- Challenges in clinical trials feasibility, site selection and patient enrollment
- Recruitment strategies in Primary Care findings from literature

Topics to be discussed

Feasibility of clinical trials in Primary Care – What about Greece

- Where to focus and what kind of clinical trials could be conducted in PHC
- Behavioral health in PHC
- Cost-effectiveness of behavioral interventions in PHC: findings from literature
- Some conclusions


Clinical Trial – what is it?

Clinical trials, also known as clinical studies, test potential treatments in human volunteers to see whether they should be approved for wider use in the general population

 A treatment could be a drug, medical device, or biologic, such as a vaccine, blood product, or gene therapy

This is the way to innovative and life-changing therapies

The drug development process




Clinical trial statistics

The total number of clinical trials is extremely growing

Expecting NCDs breakthroughs next years

Greece should be a powerful player



Source: Global Observatory on Health R&D, WHO, 15 Sep 2019

© World Health Organization 2019 | Source : Global Observatory on Health R&D (http://who.int/research-observatory/en/) Some documents in clinical trials – country and site level

Study protocol and protocol synopsis, insurance certificate

- **ICF** (Informed Consent Form) main, pregnant, genetic
- IB (Investigational Brochure)
- **PSP** (Protocol Signature Page)
 - CV, GCP, ML, CTA, Submissions to SC, Annex I, Annex II
- Medical laboratory tests and many other docs...


Challenges in clinical trials

Feasibility in clinical trial

Feasibility is the evaluation of the possibility of conducting a particular clinical trial in a particular geographical region with the overall objective of optimum project completion in terms of time lines, targets and cost

Many types of feasibilities, such as in study level and site level

Feasibility is performed under specific criteria



Site selection process

• One of the greatest challenges in clinical trial execution

• A considerable number of clinical studies experience delays

This contributes to increased duration and costs

 Terms, such as eligible for participation, eligible for activation, potential for activation etc. Factors influencing clinical trial site selection in Europe

The Survey of Attitudes towards Trial sites in Europe (SAT-EU Study)


 Investigator factors, Hospital/unit factors, Environmental factors, Cost factors (as a result costs appear less important)

Investigator factors	Environment-driven criteria	Hospital-driven criteria
Investigator recruitment/retention track record	Size of market/eligible patients in a region	Site personnel experience and training
Investigator experience in previous trials	Speed of MoH/ethics committees approval	Previous experience with site
Investigator interest	Disease management system/networks	Facilities/equipment required by trial


Patient recruitment in clinical trials

Many factors contribute to effective, high-quality clinical trials

- One of the most important sections is the enrollment, recruitment and retention of patients - identifying and recruiting patients who meet protocol criteria is challenging
- The process of enrolling patient volunteers into early phase studies
- This process affects the effectiveness of clinical trial



Recruitment strategies in primary care – patient level



242 patients (in 6 months) and at a cost of £27.66 per patient


66 patients (in 1 month) and at a cost of £2.72 per patient

Recruitment strategies in primary care – patient level

Patient incentives

\$2 incentive for joining the study, \$15 pending survey completion or the chance to win a \$200 prjze

The \$15 incentive pending survey completion yielded the greatest effect <u>Comparing waiting room patient</u> <u>screening and a practice mail-out</u>




More patients have been involved in study through mails

Source: Ngune I. et al (2012)

Recruitment strategies in primary care – Practitioner and health system level

- Peer recruitment
- Enlisting opinion leaders
- Minimising the research responsibilities of practitioners
- Recruiting practitioners who are interested in the research topic
- Professional bodies can support effectively

Recruitment and retention of patients



Source: Yifeng Liu, Emma Pencheon, Rachael Maree Hunter, et al. 2018

Why patients decline clinical trials?

1. Fear of side effects


2. Randomization

Concern about costs

Rank of Response				
STUDY	1ST	2ND	3RD	4TH
Cancer Patients				
Meropol, (2007) [72]	Fear of side effects "I fear side effects that might come with treatment on a clinical trial"	Control "I am uncomfortable with being randomly assigned (for example, a coin toss) to a treatment"	Control "I fear receiving a placebo (for example a sugar pill) on a clinical trial."	Logistics "I would be unable to fulfill trial requirements due to logistical barriers such as transportation."
Unger, (2013) [30]	Control "Random treatment, and protocol would determine care"	"Did not want treatment"	Fear of side effects "Treatment side effects"	"No personal benefit"
Lara, (2001) [139]	Control "Desire for other treatment"	Logistics "Distance from clinic"	"Unknown"	Costs "Insurance denial"
Klabunde, (1999) [111]	"Concerns about experimentation"	"Unspecified"	Costs "Concern about cost" and "Insurance refusal"	Fear of side effects "Concerns about toxicity"
Zaleta, (2017) [206] (Minorities)	Control "Feeling uncomfortable with being randomly assigned to a treatment"	Control "Fearing receiving a placebo"	Fear of side effects "Fearing side effects that may come with treatment."	Costs "Believing that health insurance would not cover a clinical trial."
Javid, (2012) [34]	Control "Did not like that protocol dictated treatment"	Fear of side effects "Concerned that offered treatment had too many side effects"	Lack of personal benefit "Did not want treatment offered on clinical trial"	Logistics "Test and procedures and getting to/from required too much effort"

Is it feasible for primary health care in Greece to be involved in clinical research? What about behavioral clinical trials?

Clinical trial approval process in Greece



RA: Regulatory Authority, NEC: National Ethics Committee, SC: Scientific Committee

What kind of clinical trials could be conducted in PHC?

Obesity – Greece has high rates of obesity and seems to be a growing health concern. Studies on diet, exercise are growing globally

- Lifestyle and Physical inactivity Only 14.1% of young people aged 11-17 years old meet the WHO recommended physical activity levels for health. This is strange if we consider that Physical education is mandatory in primary and secondary schools across Greece.
- Tobacco use Although smoking rates are declining, they're still too high in Greece compared with other countries.

What kind of clinical trials could be conducted in PHC?

Mental health disorders - Many behavioral interventions contributed to greater improvement in anxiety, depression, and quality of care (Bradford, et al., 2011; Roy-Byrne, et al., 2010; Lang, 2003)

 Diabetes – Results from interventions in Primary Care have shown treatment adherence for patients with comorbid diabetes (Lamers, Jonkers, Bosma, Knottnerus, & Van Eijk, 2011;). Interventions such as educational information, diet, exercise, social support

Pediatrics – Integrating children's behavioral health

Behavioral health in Primary Care

Primary care is the focal point of patients' health and wellbeing

Behavioral health integration in Primary Care is clinically effective

Are behavioral interventions in Primary Care cost-effective?

Cost-effectiveness of behavioral interventions in Primary Care: Findings from literature



and counseli

Patient Education and Counseling 32 (1997) 175-184

Inclusion criteria \rightarrow > 40 years or older having Type 1 or 2 Diabetes

Long term effects and costs of brief behavioural dietary intervention 1 patients with diabetes delivered from the medical office

Russell E. Glasgow^a,*, Pierre-Andre La Chance^b, Deborah J. Toobert^a, Jane Brown^a, Sarah E. Hampson^a, Matthew C. Riddle^c

^{*}Oregon Research Institute, Eugene, OR, USA ^bCentre for Health Research, Kaiser Permanente Northwest, Portland, OR, USA ^cOregon Health Sciences University, Portland, OR, USA

Received 12 December 1996; received in revised form 23 April 1997; accepted 23 April 1997

Abstract

Economic dissemination model: cost per patient for various numbers of patients seen

Intervention components	Number of patients per year		
	100	500	1000
Touch screen computer package	\$26	\$5	\$3
Materials and supplies	\$43	\$43	\$43
Labor (including benefits)	\$59	\$59	\$59
Postage	\$10	\$10	\$10
Long distance phone	< \$1	< \$1	< \$1
Total cost per patient	\$139	\$117	\$115
Cost per 1% recent reduction in fat intake	\$63	\$53	\$52
Cost per unit reduction in cholesterol	\$8.40	\$7.11	\$6.95

cant intervention effects: fat consumption, saturated fat consumption, and serum cholesterol. Since there were not significant effects on HbA. economic analyses were not conducted practical to implement in a variety of outpatient settings. The touchscreen computer is mounted on a portable cart that can be moved from one exam room to another. The intervention requires

Low cost and cost-effective intervention that contributes to long-term positive outcomes and patient satisfaction Table 3

Cost-effectiveness of behavioral interventions in Primary Care: Findings from literature

Interventions compared

- Group-based peer support
- 2) Standardized diabetes care

International Journal of Technology Assessment in Health Care, 28:1 (2012), 3-11. © Cambridge University Press 2012 doi:10.1017/\$0266462311000663

Assessments

COST EFFECTIVENESS OF PEER SUPPORT FOR TYPE 2 DIABETES

Paddy Gillespie National University of Ireland, Galway	
email: paddy.gillespie@nuigalway.ie	
Eamon O'Shea	
National University of Ireland, Galway	

Gillian Paul, Tom O'Dowd Trinity College Dublin Susan M. Smith Royal College of Surgeons Ireland

control

Objectives: The aim of this study is to examine the cost-effectiveness of a group-based peer support intervention in general practice for patients with type 2 diabetes. Methods: Incremental cost utility analysis combining within trial and beyond trial components to compare the lifetime costs and benefits of alternative strategies: Control: standardized diabetes care; Intervention: group-based peer support in addition to standardized diabetes care. Within trial analysis was based on a cluster randomized controlled trial of 395 patients with type 2 diabetes in the east of Ireland. Beyond trial analysis was conducted using the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model. Uncertainty was explored using a range of sensitivity analyses and cost-effectiveness acceptability curves were generated.

Results: Compared with the control strategy, the intervention was associated with an increase of 0.09 (95 percent confidence interval [CI], -0.05 to 0.25) in mean quality-adjusted life-years per patient and savings of €637.43 (95 percent Cl, -2455.19 to 1125.45) in mean healthcare cost per patient and €623.39 (95 percent Cl, -2507.98 to 1298.49) in mean total cost per patient respectively. The likelihood of the intervention being cost-effective was appreciably higher than 80 percent for a range of potential willingness-to-pay cost-effectiveness thresholds. Conclusions: Our results suggest that while a group-based peer support intervention shows a trend toward improved risk factor management, we found no significant differences in final cost or effectiveness endpoints between intervention and control. The probabilistic results suggest that the intervention was more cost-effective, with probability values of higher than 80 percent across a range of potential cost-effectiveness threshold values.

Keywords: Type 2 diabetes, Peer support, General practice, Cost-effectiveness analysis

Gillespie et al.

Table 4. Incremental Cost-Effectiveness Results

Variable/analysis	Incremental analysis (Intervention minus control) Mean (95% CIs)	Cost savings of €637.43 pe
Cost analysis Difference in trial based healthcare cost Difference in trial based patient cost Difference in trial based total cost	560.08 (1738.89, 618.73) 4.01 (53.63, 61.64) 527.83 (1744.42, 688.75)	patient in healthcare costs
Lifetime healthcare cost Difference in lifetime healthcare cost Lifetime total cost Difference in lifetime total cost	17176.93 (16105.03, 18464.17) -637.43 - 2445.19, 1125.45) 17487.81 (16233.23, 18985.85) -623.39 (-2507.98, 1298.49)	
Effectiveness analysis Lifetime QALYs Difference in QALYs	Intervention 6.76 (6.66,6.86) 0.09 (-0.05, 0.25) 0.09 (-0.05, 0.25)	Increase in QALYs (0.09 per patient compared with contro

*Note, Within Trial Analyses: M*ultilevel GEE regression model, with identity link tunction, Gamma variance function (Gaussian for Patient Cost), and exchangeable correlation structure. All models estimated controlling for treatment group and baseline cost for the 12 months before the trial.

Beyond Trial Analyses: Based on 10,000 Monte Carlo simulations in the UKPDS Outcomes model and 1,000 Monte Carlo simulations to combine within and beyond trial results

Nowadays, organizations strongly recommend primary care interventions

Search USPSTF Website U.S. Preventive Services Α E-mail Updates 🔹 Text size: 👔 A TASK FORCE Home You are here: Home >> Recommendations for Primary Care Practice >> Published Recommendations >> Recommendation Summary » Final Recommendation Statement : Final Recommendation Statement Recommendations Final Recommendation Statement Published Final Recommendations Tobacco Use in Children and Adolescents: Primary Care Interventions Recommendations in Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Progress **Copyright Notice Recommendation Summary** Information for Health Professionals Summary of Recommendation and Evidence Information for Population Recommendation Grade Consumers (What's This?) Public Comments and School-Aged Children and The USPSTF recommends that primary care clinicians provide interventions, B Adolescents including education or brief counseling, to prevent initiation of tobacco use Nominations among school-aged children and adolescents. See the Clinical Considerations for more information on effective interventions Methods and Processes About the USPSTF Return to Table of Contents A

The United States Preventive Services Task Force

Some conclusions

Clinical trials are investments for public health

Twenty-first century primary care is rapidly evolving. In Greece, we have to speed up

 Greece has to retain it's high quality Family Physicians - Family physicians play a key role in healthcare delivery

They could play a vital role in integrating behavioral studies in primary health system in Greece

Is this the answer to boost clinical research in Primary Care?

Scandinavian Journal of Primary Health Care, 2014; 32: 107-109

EDITORIAL

Research networks in primary care: An answer to the call for better clinical research



Nasjonalt senter for e-helseforskning

The Norwegian Primary Care Research Network

Guri Rørtveit Project leader, UiB

Project group: Jørund Straand, UiO Knut-Arne Wensaas, Uni Research Health Peder Halvorsen, UiT Egil Fors, NTNU Svein Gjelstad, UiO Gustav Bellika, NSE/UNN





We are a national network of GP practices whose purpose is to participate in clinical research for the benefit of their patients and to enhance the discipline of general practice through research training and activity.

THE IRISH PRIMARY CARE RESEARCH

What is the IPCRN

The trait College of General Practitioners (CCIP), the HRB Centre for Primary Care Research in the Rayal College of Surgeons in Inclead (RCS) and Western Research and Education Network at the National University of Inclead Gelway (NUR6) are currently collaborating to create an Irish Primary Care Research Network (PCR-N).

More Details

View IPCRN Data

View data from some of our research projects and find out more information about working with the IPCRN.

If you are a GP, learn how the IPCRN can help you in the areas of audit and research and manage your patient care More Details

Collaborate with the IPCRN

If you are interested in collaborating with the IPCRN, Please contact us for further information.

Thank you in advance!

konzis1988@gmail.com